Tacrolimus ameliorates the phenotypes of type 4 Bartter syndrome model mice through activation of sodium–potassium–2 chloride cotransporter and sodium–chloride cotransporter
2019
Abstract Type4
Bartter syndrome(BS) is caused by genetic mutations in barttin, which is coded for by BSND. Barttin serves as the β-subunit of the ClC–K chloride (Cl−) channel, which is widely expressed in distal
nephrons. Type 4 BS is characterized by severely impaired reabsorption of salt, which may cause
polyuria,
hypokalemia, and
metabolic alkalosis.
Calcineurininhibitors reportedly induce renal salt retention and
hyperkalemiaby enhancing the phosphorylation of the sodium (Na+)–potassium (K+)–2Cl−
cotransporter(NKCC2) and Na+–Cl−
cotransporter(NCC). In addition, we have previously reported that
tacrolimus, a
calcineurininhibitor, increases the levels of phosphorylated NCC. In this study, we administered
tacrolimusto barttin hypomorphic (Bsndneo/neo) mice, a murine model of type 4 BS that exhibits
polyuria,
hypokalemia, and
metabolic alkalosis. Administration of
tacrolimusincreased the serum K+ level and suppressed urinary K+ excretion. Furthermore, after treatment with
tacrolimus, Bsndneo/neo mice increased levels of phosphorylated NCC and NKCC2. We conclude that
tacrolimuspartially improves clinical phenotypes of Bsndneo/neo mice, and that
calcineurininhibitors might be effective for treating type 4 BS.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
27
References
0
Citations
NaN
KQI